BDX
BuyFull HouseAPPROVEBecton, Dickinson and Company · Healthcare · United States · $51.6B · Avg Vol: $330M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Becton Dickinson clears the calibrated bar. All three legs are above the floor (Q56 V67 M60) and an active buyback provides the required corroboration. Nothing adverse survives the evidence test: the only insider figure on file is selling that rounds to 0.00% of shares outstanding, which the framework treats as unusable rather than adverse, and there is no negative earnings revision. Medical device demand is defensive, with a large recurring consumables base insulated from the squeezed-consumer theme.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT BECTON, DICKINSON AND COMPANY
Read
Becton, Dickinson and Company (BD) is a global medical technology company developing, manufacturing, and selling medical devices, instrument systems, and reagents. BD is a market leader in critical healthcare segments like medication management, infection prevention, and diagnostic systems, supported by a vast intellectual property portfolio and global distribution. It is a highly diversified and essential supplier to the global healthcare industry, known for its broad product portfolio and significant installed base.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.9B | 19.4B | 20.2B | 21.8B | 5.0% | 22.5B | 19.3B | 19.7B | -4.9% |
| EPS | 5.93 | 4.97 | 5.96 | 5.83 | -0.6% | 5.79 | 5.11 | 5.38 | -3.9% |
| Shares | 283.4M | 290.4M | 289.1M | 285.4M | +0.7% | 272.4M | — | — | — |
| Debt | 16.1B | 15.9B | 20.1B | 19.2B | 6.1% | 16.8B | — | — | — |
| Equity | 25.3B | 25.8B | 25.9B | 25.4B | 0.1% | — | — | — | — |
| Op CF | 2.6B | 3.0B | 3.8B | 3.4B | 9.2% | 3.3B | — | — | — |
| Inv CF | -3.2B | -716.0M | -5.5B | -818.0M | — | — | — | — | — |
| Fin CF | -591.0M | -2.0B | 2.1B | -3.6B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BDX | Becton, Dickinson and Company(you) | $51.6B | 77 | Buy |
| 7741.T | HOYA Corporation | $51.0B | 64 | Hold |
| RMD | ResMed Inc. | $34.7B | 87 | Strong Buy |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| 4543.T | Terumo Corporation | $23.4B | 82 | Strong Buy |
| STMN.SW | Straumann Holding AG | $18.4B | 77 | Buy |
| FPH.AX | Fisher & Paykel Healthcare Corporation Limited | $15.3B | 77 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| CBHD.DE | Coloplast A/S | $16.1B | 70 | Buy |
| ALC.SW | Alcon Inc. | $34.6B | 55 | Hold |
Peer medians: ROE 2.7% · P/E 23.5x · Gross margin 52.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.